Senseonics(SENS)2025-03-03 21:09Financial Performance - The Company reported a preliminary unaudited revenue of approximately 22.5 million for the full year ended December 31, 2024[11]. - The unaudited balance of cash, cash equivalents, and restricted cash as of December 31, 2024, is expected to be approximately $74.9 million[11]. - Total unaudited operating expenses and associated cash utilization for Q4 2024 and the full year 2024 were consistent with the Company's previously provided guidance[11]. - The financial information presented is preliminary and has not been reviewed or audited by the Company's independent registered public accounting firm[9]. - The Company anticipates that actual audited financial results may differ from the preliminary financial information provided[9]. Patient Growth - The Company's patient base increased by 56% in 2024 compared to 2023, reaching approximately 6,000 global patients[7]. Corporate Actions - The Company announced the cancellation of the Special Meeting of Stockholders originally scheduled for January 10, 2025, regarding a proposed reverse stock split[6]. Forward-Looking Statements - Forward-looking statements regarding future expectations and plans are subject to various important factors that may cause actual results to differ materially[8]. Company Classification - The Company is classified as an emerging growth company under the Securities Act of 1933[3]. Press Release - The press release detailing these updates was issued on January 8, 2025[4].